GlassScriptPhysician profile
Mohamad Soud
NPI 1003278292
$7,500.08
in general payments reported to CMS, 2019-2025
21 companies · $572 in 2025
The $572 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,660 · 2022: $4,503 · 2023: $613 · 2024: $151 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $89.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.69 |
| Education | $89.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,098.41 | 2021-2023 | In.Pact Admiral, Hawkone |
| Boston Scientific Corporation | $2,971.33 | 2022-2025 | Mamba, Wolverine Coronary Cutting Balloon |
| Cardiva Medical, INC. | $435.14 | 2022 | |
| Inari Medical, INC. | $249.09 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abiomed | $97.43 | 2025 | |
| Shockwave Medical, INC | $89.99 | 2025 | |
| Chiesi USA, INC. | $79.02 | 2022 | |
| Irhythm Technologies, INC. | $70.35 | 2024 | Zio Monitor, Zio Xt Patch |
| Amgen INC. | $56.98 | 2025 | Repatha |
| Abbott Laboratories | $47.89 | 2023 | Optis |
| E.R. Squibb & Sons, L.L.C. | $47.64 | 2025 | Camzyos, Eliquis |
| Heartflow, INC. | $47.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.83 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $30.70 | 2024-2025 | Lokelma |
| Lantheus Medical Imaging, INC. | $27.80 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $23.32 | 2025 | |
| Lilly USA, LLC | $20.84 | 2024 | Mounjaro |
| Terumo Medical Corporation | $20.35 | 2023 | Tr Band, Glidewire, Heartrail |
| Regeneron Healthcare Solutions, INC. | $18.75 | 2024 | Evkeeza |
| Biotronik INC. | $16.85 | 2021 | |
| Cardiovascular Systems INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamad Soud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.